Zacks Investment Research on MSN

Will Rybelsus' Updated EU Label Propel Fresh Growth Potential for NVO?

Novo Nordisk NVO has secured European approval to update the label of oral GLP-1 drug for type II diabetes (T2D), Rybelsus ...

Here's Novo Nordisk's First Oral Obesity Drug In Europe With Proven Heart Health Impact

Committee for Medicinal Products for Human Use (CHMP) approved an update to Novo Nordisk A/S‘ (NYSE:NVO) Rybelsus (oral ...
Pharmaceutical Technology on MSN

Novo Nordisk secures EMA approval for Rybelsus label update

Rybelsus becomes the first oral glucagon-like peptide-1 receptor agonist in the EU with proven cardiovascular benefits.
PharmiWeb

EU approval makes Novo Nordisk’s oral semaglutide the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke

Bagsværd, Denmark, 15 September 2025 – Novo Nordisk today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has approved an update to the ...
PharmExec

Novo Nordisk’s Rybelsus Becomes First EU Approved Oral GLP-1 Reducing Severe Cardiovascular Events

Novo Nordisk's Rybelsus gains EU approval for cardiovascular benefits, enhancing treatment options for type 2 diabetes and ...
Medical Dialogues

EMA Committee approves update to Novo Nordisk Rybelsus label to reflect cardiovascular benefits

Denmark: Novo Nordisk has announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use ...
The Pharma Letter

EU approves update for Novo Nordisk’s oral semaglutide in cardio risk reduction

Committee for Medicinal Products for Human Use (CHMP) has approved Danish pharma major Novo Nordisk’s update to the Rybelsus ...
Pharmabiz

Novo Nordisk announces Ozempic reduces the risk of heart attack, stroke and death by 23% compared to dulaglutide in the first head-to-head real-world study

Bagsværd, Denmark Saturday, September 20, 2025, 11:00 Hrs [IST] ...
Zacks.com on MSN

Can Novo Nordisk Hold Its Edge as the GLP-1 Battle With LLY Heats Up?

NVO gains ground in the GLP-1 battle as Ozempic outshines Trulicity in heart risk reduction and Rybelsus wins EU approval for ...
Medical Marketing & Media

Rx Rundown: Novo Nordisk, Servier, Novartis and more

Novartis is set to acquire Tourmaline Bio for $1.4 billion. Servier buys Medicxi startup’s fragile X candidate for up to $450 million. Sandoz and Regeneron reached an agreement, resolving all patent ...

Arch Strengthens its Position as a Leading Kidney Therapeutics Company with the Acquisition of a Breakthrough Platform to Develop New Drugs Targeting Chronic Kidney Disease (CKD)

Arch acquires a new CKD platform that has the potential to produce next-generation CKD drugs for the pharmaceutical industryBased on a novel ...